HK1222559A1 - 使用貝那利珠單抗增加哮喘患者用力呼氣量的方法 - Google Patents

使用貝那利珠單抗增加哮喘患者用力呼氣量的方法 Download PDF

Info

Publication number
HK1222559A1
HK1222559A1 HK16110776.1A HK16110776A HK1222559A1 HK 1222559 A1 HK1222559 A1 HK 1222559A1 HK 16110776 A HK16110776 A HK 16110776A HK 1222559 A1 HK1222559 A1 HK 1222559A1
Authority
HK
Hong Kong
Prior art keywords
benralizumab
antigen
binding fragment
weeks
patient
Prior art date
Application number
HK16110776.1A
Other languages
English (en)
Chinese (zh)
Inventor
‧沃德
C‧沃德
‧羅斯科斯
L‧罗斯科斯
王冰
‧雷布爾
D‧雷布尔
Original Assignee
米迪缪尼有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 米迪缪尼有限公司 filed Critical 米迪缪尼有限公司
Publication of HK1222559A1 publication Critical patent/HK1222559A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
HK16110776.1A 2013-08-12 2014-08-07 使用貝那利珠單抗增加哮喘患者用力呼氣量的方法 HK1222559A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
US61/864,948 2013-08-12
PCT/US2014/050119 WO2015023507A2 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK42021024819.1A Addition HK40035227A (en) 2013-08-12 2016-09-12 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Publications (1)

Publication Number Publication Date
HK1222559A1 true HK1222559A1 (zh) 2017-07-07

Family

ID=52448838

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110776.1A HK1222559A1 (zh) 2013-08-12 2014-08-07 使用貝那利珠單抗增加哮喘患者用力呼氣量的方法

Country Status (26)

Country Link
US (1) US9441046B2 (cg-RX-API-DMAC7.html)
EP (5) EP3033104B1 (cg-RX-API-DMAC7.html)
JP (4) JP6746496B2 (cg-RX-API-DMAC7.html)
KR (1) KR102337599B1 (cg-RX-API-DMAC7.html)
CN (2) CN105451769A (cg-RX-API-DMAC7.html)
AU (2) AU2014306959B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016002317A8 (cg-RX-API-DMAC7.html)
CA (1) CA2917603C (cg-RX-API-DMAC7.html)
CY (2) CY1122033T1 (cg-RX-API-DMAC7.html)
DK (2) DK3520811T3 (cg-RX-API-DMAC7.html)
ES (2) ES2866426T3 (cg-RX-API-DMAC7.html)
HK (1) HK1222559A1 (cg-RX-API-DMAC7.html)
HR (2) HRP20190920T1 (cg-RX-API-DMAC7.html)
HU (2) HUE053627T2 (cg-RX-API-DMAC7.html)
LT (2) LT3033104T (cg-RX-API-DMAC7.html)
ME (1) ME03403B (cg-RX-API-DMAC7.html)
MX (2) MX381102B (cg-RX-API-DMAC7.html)
PL (2) PL3520811T3 (cg-RX-API-DMAC7.html)
PT (2) PT3033104T (cg-RX-API-DMAC7.html)
RS (2) RS58711B1 (cg-RX-API-DMAC7.html)
RU (1) RU2703568C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201600483QA (cg-RX-API-DMAC7.html)
SI (2) SI3520811T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201900311T1 (cg-RX-API-DMAC7.html)
TR (1) TR201907907T4 (cg-RX-API-DMAC7.html)
WO (1) WO2015023507A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
BR112016002462A8 (pt) * 2013-08-12 2018-06-12 Medimmune Llc Métodos para melhorar os sintomas da asma usando benralizumabe
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
LT3060229T (lt) * 2013-10-24 2021-09-27 Astrazeneca Ab Stabilios vandeninės antikūno vaistinės formos
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2026053166A1 (en) * 2024-09-06 2026-03-12 Medimmune Limited Anti-il5r-alpha treatment for acute exacerbations of asthma and copd

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2001060405A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
PT3072525T (pt) * 2007-05-14 2018-04-20 Astrazeneca Ab Métodos para reduzir os níveis de basófilos
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
KR101615420B1 (ko) * 2010-12-16 2016-04-26 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
WO2012158954A1 (en) 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
CN104039352A (zh) 2011-11-01 2014-09-10 米迪缪尼有限公司 用于降低哮喘急性恶化的频率和严重性的方法
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
BR112016002462A8 (pt) * 2013-08-12 2018-06-12 Medimmune Llc Métodos para melhorar os sintomas da asma usando benralizumabe

Also Published As

Publication number Publication date
HRP20210406T1 (hr) 2021-04-30
ES2866426T3 (es) 2021-10-19
CY1124399T1 (el) 2022-07-22
DK3033104T3 (da) 2019-06-17
EP3033104A2 (en) 2016-06-22
CY1122033T1 (el) 2020-10-14
PL3520811T3 (pl) 2021-08-02
JP6746496B2 (ja) 2020-08-26
LT3520811T (lt) 2021-03-25
JP2016527325A (ja) 2016-09-08
CN111588849A (zh) 2020-08-28
SG11201600483QA (en) 2016-02-26
WO2015023507A3 (en) 2015-04-09
CA2917603A1 (en) 2015-02-19
ES2733602T3 (es) 2019-12-02
PT3520811T (pt) 2021-03-15
EP4579236A3 (en) 2025-09-17
BR112016002317A8 (pt) 2018-06-12
PT3033104T (pt) 2019-06-27
SI3520811T1 (sl) 2021-04-30
US9441046B2 (en) 2016-09-13
RU2016108809A (ru) 2017-09-18
US20150044203A1 (en) 2015-02-12
RS61565B1 (sr) 2021-04-29
EP4579236A2 (en) 2025-07-02
WO2015023507A8 (en) 2015-09-24
WO2015023507A2 (en) 2015-02-19
CA2917603C (en) 2023-05-16
KR20160043049A (ko) 2016-04-20
BR112016002317A2 (pt) 2017-12-12
CN105451769A (zh) 2016-03-30
EP3520811B1 (en) 2020-12-30
KR102337599B1 (ko) 2021-12-10
RS58711B1 (sr) 2019-06-28
AU2014306959B2 (en) 2019-11-21
HUE043497T2 (hu) 2019-08-28
RU2016108809A3 (cg-RX-API-DMAC7.html) 2018-06-18
EP3875487A1 (en) 2021-09-08
AU2020201277A1 (en) 2020-03-12
SMT201900311T1 (it) 2019-07-11
RU2703568C2 (ru) 2019-10-21
DK3520811T3 (da) 2021-03-22
JP2020125304A (ja) 2020-08-20
JP7864776B2 (ja) 2026-05-25
EP3033104B1 (en) 2019-04-03
MX2016001384A (es) 2016-08-03
HRP20190920T1 (hr) 2019-07-12
AU2014306959A1 (en) 2016-02-04
MX2021003826A (es) 2021-05-27
EP4636400A2 (en) 2025-10-22
SMT202100152T1 (it) 2021-05-07
PL3033104T3 (pl) 2019-09-30
HUE053627T2 (hu) 2021-07-28
TR201907907T4 (tr) 2019-06-21
EP4636400A3 (en) 2025-12-24
EP3033104A4 (en) 2017-03-22
EP3520811A1 (en) 2019-08-07
MX381102B (es) 2025-03-12
SI3033104T1 (sl) 2019-06-28
HK1225300A1 (en) 2017-09-08
LT3033104T (lt) 2019-06-25
JP2024129140A (ja) 2024-09-26
ME03403B (me) 2020-01-20
JP2022120010A (ja) 2022-08-17

Similar Documents

Publication Publication Date Title
CN111588849A (zh) 使用贝那利珠单抗增加哮喘患者用力呼气量的方法
US9441037B2 (en) Methods for reducing exacerbation rates of asthma using benralizumab
HK1225302A1 (en) Methods for reducing exacerbation rates of asthma using benralizumab
HK1221647A1 (zh) 使用貝那利珠單抗改善哮喘症狀的方法
HK40035227A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40129473A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40058739A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
RU2840902C2 (ru) Способы нормализации симптомов астмы с применением бенрализумаба
HK40012636A (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40012636B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK1225300B (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
HK40035226A (en) Methods for reducing exacerbation rates of asthma using benralizumab
HK40035228A (en) Methods for improving asthma symptoms using benralizumab